Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Kathleen Colson"'
Autor:
Jacob P. Laubach, Sascha A. Tuchman, Jacalyn M. Rosenblatt, Constantine S. Mitsiades, Kathleen Colson, Kelly Masone, Diane Warren, Robert A. Redd, Dena Grayson, Paul G. Richardson
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Abstract Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50–77])
Externí odkaz:
https://doaj.org/article/5656ab9a54f64dc2a200aac3cf4c933c
Autor:
Paul G. Richardson, Arnon Nagler, Dina Ben‐Yehuda, Ashraf Badros, Parameswaran N. Hari, Roman Hajek, Ivan Spicka, Hakan Kaya, Richard LeBlanc, Sung‐Soo Yoon, Kihyun Kim, Joaquin Martinez‐Lopez, Moshe Mittelman, Ofer Shpilberg, Paul Blake, Teru Hideshima, Kathleen Colson, Jacob P. Laubach, Irene M. Ghobrial, Merav Leiba, Moshe E. Gatt, Peter Sportelli, Michael Chen, Kenneth C. Anderson
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 94-102 (2020)
Abstract Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti‐MM activity in preclinical studies and encourag
Externí odkaz:
https://doaj.org/article/4446319b4078465e9e6ff60dab4bc36c
Autor:
Jacalyn Rosenblatt, Diane Warren, Kelly Masone, Dena Grayson, Sascha A. Tuchman, Kathleen Colson, Paul G. Richardson, Jacob P. Laubach, Robert A. Redd, Constantine S. Mitsiades
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50–77]) and a med
Publikováno v:
Clinical journal of oncology nursing. 25(6)
Background Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed/refractory multiple myeloma who have received at least two prior therapies. Because isatuximab is a
Autor:
Kenneth C. Anderson, Clifton C. Mo, Omar Nadeem, Kelly Masone, Ella L Millard, Irene M. Ghobrial, Giada Bianchi, Mary McKenney, Isabella Hou, Peter Barth, Kathleen Colson, Jacob P. Laubach, Leyla Shune, Virginia Dalton, Paul G. Richardson, Adam S. Sperling, Robert A. Redd, Alexandra Savell, Vaishali Sanchorawala, Nikhil C. Munshi, Laura N. Amweg, Trevor J. Bayliss, Alexandra Distaso
Publikováno v:
Blood
Introduction: Treatment of relapsed and refractory multiple myeloma (RRMM) continues to evolve as most patients are lenalidomide (LEN) refractory at the time of first relapse with its widespread use in both induction and maintenance therapy. Pomalido
Autor:
Ofer Shpilberg, Irene M. Ghobrial, Moshe Mittelman, Ashraf Badros, Ivan Spicka, Arnon Nagler, Kenneth C. Anderson, Richard Leblanc, Jacob P. Laubach, Kihyun Kim, Teru Hideshima, Peter Sportelli, Paul Blake, Paul G. Richardson, Moshe E. Gatt, Merav Leiba, Sung-Soo Yoon, Michael Chen, Kathleen Colson, Roman Hájek, Hakan Kaya, Joaquin Martinez-Lopez, Parameswaran Hari, Dina Ben-Yehuda
Publikováno v:
EJHaem. 1(1)
Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti-MM activity in preclinical studies and encouraging early-p
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S289
Context: Isatuximab (Isa) is a monoclonal antibody that binds to a specific epitope on CD38 and triggers death of multiple myeloma (MM) cells. Isatuximab-irfc is FDA-approved in combination with pomalidomide and dexamethasone (Pd) to treat adults wit
Autor:
Beth Faiman, Deborah Doss, Kathleen Colson, Patricia Mangan, Tracy King, Joseph Tariman, and Board
Publikováno v:
Clinical journal of oncology nursing. 21
BACKGROUND A majority of patients with multiple myeloma experience damage to the kidneys and peripheral nerves either at diagnosis or throughout the disease. Symptoms of diarrhea, nausea, vomiting, or constipation can also occur. Prevention and manag
Autor:
Kimberly Noonan, Kathleen Colson
Publikováno v:
Seminars in oncology nursing. 33(3)
Objective To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). Data Sources Journal articles, research reports, state of the science papers, and clinic
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam